VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ASCO 2021 | Cardiac safety in the APHINITY study

It is known that trastuzumab increases the incidence of cardiac events in patients with early breast cancer. In this interview, Evandro de Azambuja, MD, PhD, L’Universite Libre de Bruxelles, Brussels, Belgium, analyzes the cardiac safety of dual blockade with pertuzumab and trastuzumab in patients enrolled in APHINITY (NCT01358877). Dual blockade does not increase the risk of cardiac events compared to platinum agents and trastuzumab alone. In patients with cardiovascular risk factors, non-anthracycline-based chemotherapy regimens should be considered. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.

Disclosures

Evandro de Azambuja, MD, PhD, has received honoraria and advisory board roles from Roche/GNE, Novartis, Seattle Genetics, Zodiacs, Lilly, Libbs and Pierre Fabre; travel grants from Roche/GNE and GSK/Novartis; research grants for his institute (IJB) from Roche/GNE, Astra-Zeneca, Novartis, and Servier.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter